# Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer

> **NCT00191568** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 45 (—)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **PROCEDURE:** Radiotherapy

## Key facts

- **NCT ID:** NCT00191568
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 45 (—)
- **Last updated:** 2007-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191568, "Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00191568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*